Radishes Are the Detoxifying Veggie to Rediscover This Summer
Summer is synonymous with salads—ideally, as crisp, colorful, and refreshing as possible. But when the usual arugula, cherry tomato, carrots, and cucumbers, starts to feel same-old, there's one crisp vegetable that shouldn't be forgotten: radishes. In season from May to September, they lend a vibrant touch to every dish.
They're not just tasty, either. Rich in vitamin C, antioxidants such as lutein and zeaxanthin, and minerals such as potassium and calcium, radishes provide vital nutrients. Not to mention: They're also surprisingly hydrating and detoxifying. In fact, they've been used for ages in traditional Chinese and Ayurvedic medicine thanks to their purported therapeutic properties.
The beauty of radishes
Radishes, or Rapahnus sativus, are the roots of a herbaceous plant from the Brassicaceae or cruciferous family, which also includes broccoli, kale, and Brussels sprouts. Native to Asia but found growing wild and cultivated in Europe and America as well, radishes can be eaten root to tip; the tender, young leaves of the plant are delicious in salads and soups.
There are a lot of different types of radishes, in a range of shapes, flavors, and colors. Think: white like daikon, super-spicy Japanese radish, purple radish, watermelon, and even black. However, you're probably most familiar with the bright red radishes that are common in North America and Europe.
The benefits of radishes
When eaten raw, the benefits of radishes make them a welcome addition to our dietary repertoire. Though low in calories, they're high in fiber, which is ideal for providing a sense of satiety and stimulating digestion and the intestinal tract. They possess a low glycemic index, have a mild diuretic effect. Composed of 95 percent water, they're helpful for fighting summer dehydration, and for detoxifying and protecting the liver. They're also high in potassium, which helps protect against high blood pressure.
Radishes are rich in the antioxidant vitamin C, which can help stimulate collagen production, nourish the skin, and strengthen the immune system. They also have antifungal properties due to the presence of the RsAFP2 protein, which according to one study, can also fight Candida Albicans, also known as yeast or thrush.
Who shouldn't eat radishes?
If you're suffering from gastritis, gastroesophageal reflux, or colitis, you should limit your consumption of radishes as they may worsen their symptoms.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
38 minutes ago
- CBS News
5 medical debt relief options that actually work
We may receive commissions from some links to products on this page. Promotions are subject to availability and retailer terms. If you're struggling under the weight of your medical debt, there are ways to get some much-needed relief. Getty Images The cost of healthcare in the U.S. has always been high, but for many Americans, the issue has gone from frustrating to financially devastating. More than 41% of adults are now carrying some form of healthcare-related debt, according to a recent KFF Health Care Debt Survey — which includes healthcare debts owed to credit cards, collections agencies, family and friends, banks and other lenders. And it's not just those without insurance who are facing this type of issue. Those with coverage are also falling behind due to issues with high deductibles, denied claims and unexpected bills that show up months later. What makes medical debt especially tricky is that it often stems from emergencies or unexpected diagnoses. Unlike credit card debt or personal loans, where you knowingly agree to borrow money, medical debt is something most people don't willingly sign up for. They get sick, they get care and then get stuck with a bill they can't afford. And, to make matters worse, some unpaid medical debt can show up on your credit report or get sent to collections, creating even more financial stress. If you're struggling with medical bills, though, you do have some options to consider. Healthcare providers, government programs and debt relief organizations offer various pathways to reduce or eliminate medical debt, but to take advantage of this type of relief, you'll need to know which options are available and how to navigate them effectively. Find out how you can start tackling your debt problems now. 5 medical debt relief options that actually work Here are some of the most effective ways to deal with overwhelming medical debt right now: Negotiate directly with the provider Before you take a more drastic step, try calling the hospital or provider's billing office about your medical debt. Many healthcare providers are surprisingly open to negotiating, especially if you're willing to pay a portion of the bill upfront. By doing this, you may be able to: Settle the debt for less than the full amount Set up a low-rate or interest-free payment plan Access discounts for uninsured or low-income patients In some cases, nonprofit hospitals are even required to offer financial assistance under federal law, so it may pay to ask about the programs available to you. Explore how debt relief could help get your finances back on track. Apply for hospital financial assistance or charity care If your income is below a certain threshold, you might qualify for your bill to be reduced or forgiven altogether. These programs, often referred to as charity care, are offered by most nonprofit hospitals, and they often go unused simply because patients don't know they exist. Eligibility varies, but in general, if you earn below 200% to 400% of the federal poverty level, you could be a candidate. Make sure to submit your application as soon as possible, ideally before the bill is sent to collections. Use a medical bill advocate A medical billing advocate is like a detective for your healthcare expenses. They'll go through your bills line-by-line to catch errors, double charges or services you shouldn't have been billed for at all. Studies have shown that the majority of medical bills contain some kind of mistake, so taking this route could pay off. These services aren't free, though. Some advocates charge a flat fee or a percentage of the savings while others work on a contingency basis, meaning you don't pay unless they lower your bill. But if your bill is over $1,000 or looks confusing, it may be worth the extra cost. Enroll in a debt consolidation or debt management program If your medical debt is mixed in with credit card debt — let's say you used a credit card to pay for procedures — then a traditional debt relief strategy, like debt consolidation, could help. A debt consolidation loan can be used to combine multiple debts into a single monthly payment, typically at a lower interest rate than your credit cards. This won't reduce the total you owe, but it can make the repayment process more manageable. You also have the option of working with a credit counseling agency to create a debt management plan, which allows them to negotiate lower interest rates and handle disbursing the monthly payments for you. You make one payment to the credit counseling agency each month and the money is then used by the credit counseling agency to pay your creditors. If you want to take this route, though, just be cautious of companies that promise quick fixes and always verify credentials before signing up. Consider debt settlement (with caution) Pursuing debt settlement is also an option (though it should be a last resort in most cases), especially if your medical debt is already in collections and you're unable to pay in full. You or a professional debt relief expert can offer a lump sum payment that's less than what you owe in exchange for clearing the debt. Many debt collection agencies will accept 50% to 70% of the total balance. This strategy has risks, though. Settled debt can hurt your credit score, and if you work with a for-profit company, you'll also have to pay fees on your settled debt. Any forgiven debt over $600 may also be considered taxable income by the IRS, so weigh the pros and cons carefully. The bottom line Medical debt can feel crushing, especially when it comes on the heels of a health scare or emergency, but there are more ways to get help than you might think. From negotiating with providers to applying for financial assistance or exploring traditional debt relief options, there are real, actionable ways to take control of your situation. But if you want to maximize the chances of a positive outcome, make sure to start the process early if possible. The sooner you explore your options, the more likely you are to avoid lasting damage — and maybe even save more money in the process.
Fox News
an hour ago
- Fox News
'Grey's Anatomy' alum Eric Dane prepared to go to extreme measures to fight ALS
Eric Dane is prepared to go to extreme measures to fight ALS. "I will fly to Germany and eat the head off a rattlesnake if [doctors] told me that that would help," the 52-year-old "Grey's Anatomy" alum told Diane Sawyer during a sit-down interview on "Good Morning America." "I'll assume the risk." During the interview, which aired Tuesday, Dane opened up about the debilitating disease and explained how he's found hope in the physician who has been leading his care. "I'm very hopeful... I don't think this is the end of my story," he said. "And whether it is or it isn't, I'm gonna carry that idea with me. "That's what I got from [Dr. Merit Cudkowicz] when I met her... there was a sense of hope I didn't get from other doctors that I met with," Dane said of his doctor, a neurologist and leading ALS researcher. Dane said that he had spoken previously with an organization that told him his doctors would be "there to... monitor my decline — and that's not very helpful." Dr. Cudkowicz said the risk factors behind the disease can include anything from environmental concerns like plastics and bacteria in lakes to sports injuries. "We worry about head trauma because we do see ALS more common in people in certain sports like football or soccer. We worry about pesticides as well. Being in the military is a risk factor," she said. "Those are the ones we know about, but there's many more we don't know about. "There's people all over the world working on this," she said, referring to ALS research. "Between artificial intelligence and other imaging technology, that's what gets me excited, and that's all coming in the next, I think, one to two years, if not faster." Dane, who revealed his diagnosis in April, said in another segment of the interview that aired Monday that he first started experiencing weakness in his right hand before seeking medical attention. "I didn't really think anything of it at the time," he told Sawyer. "I thought maybe I'd been texting too much and my hand was fatigued. A few weeks later, I noticed it'd gotten a little worse. I went and saw a hand specialist, who sent me to another hand specialist. I went and saw a neurologist, and the neurologist sent me to another neurologist and said, 'This is way above my pay grade.' "I have one functioning arm," he said. "My left side is functioning. My right side has completely stopped working. [My left arm] is going. I feel like maybe a couple, a few more months, and I won't have my left hand either. It's sobering." He said that for now, he is able to walk, but added, "I'm worried about my legs." Dane admitted that he will "never forget" the moment he was diagnosed. "I will never forget those three letters, [ALS]. It's on me the second I wake up," he said. "It's not a dream." The actor, who shares two daughters, Billie, 15, and Georgia, 13, with wife Rebecca Gayheart, said he began noticing more of the effects of his disease a few months ago during a boating trip with his daughter. After jumping into the water, Dane — a former competitive swimmer — quickly realized he was not able to swim. "[Georgia] dragged me back to the boat," said Dane, who recalled immediately breaking down in tears once on the boat. "I was just, I was, like, heartbroken." Dane also told Sawyer that he is "angry" about the diagnosis, explaining, "I'm angry because my father was taken from me when I was young, and now there's a very good chance that I'm going to be taken from my girls while they're very young." "I mean, I really, at the end of the day, just, all I want to do is spend time with my family and work a little bit if I can," he added. Fox News Digital's Janelle Ash contributed to this post.
Medscape
2 hours ago
- Medscape
Integrating CAR T and Bispecific Antibodies in MM Treatment
MILAN — The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has shifted dramatically with the emergence of immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (bsAbs). These novel approaches have delivered unprecedented outcomes in heavily pretreated patients. Yet determining the optimal treatment strategy remains a clinical challenge. Here at the 2025 European Hematology Association (EHA) Annual Meeting in Milan, Italy, leading experts weighed the strengths and limitations of both approaches, emphasizing that it is not a contest of superiority but a question of sequence and patient selection. Bispecific Antibodies: Off-the-Shelf Convenience With Strong Responses BsAbs work by redirecting T cells toward myeloma cells, binding simultaneously to a tumor antigen and CD3. In his presentation, Philippe Moreau, MD, head of the hematology department at the University Hospital of Nantes, France, reviewed the four agents approved in Europe: teclistamab, elranatamab, and linvoseltamab, which target beta cell maturation antigen (BCMA); and talquetamab, which targets G protein-coupled receptor class C group 5 member D (GPRC5D). These agents deliver overall response rates (ORRs) of 60%-70% in heavily pretreated patients, with median progression-free survival (PFS) of 12-18 months and overall survival (OS) of 24-30 months. Talquetamab in particular induces rapid responses within 1 month but is associated with unique toxicities — such as skin reactions, dysgeusia, and mucosal effects — related to GPRC5D expression in nonhematopoietic tissues like skin. BsAbs offer immediate treatment without the delays associated with CAR T manufacturing. They are also viable for frail patients and more broadly accessible outside of specialized centers. Toxicities, including cytokine release syndrome and infections, are generally manageable with step-up dosing and prophylactic tocilizumab. However, resistance remains a main concern. Roughly one third of patients — particularly those with high-risk cytogenetics, International Staging System stage III disease, or extramedullary disease — exhibit primary resistance. CAR T-Cell Therapy: Durable Outcomes With Earlier Use CAR T-cell therapies have redefined expectations in RRMM, particularly with ciltacabtagene autoleucel, which has achieved a median PFS of 35 months and a median OS approaching 61 months in heavily pretreated populations. Notably, recent data show that one third of patients remain progression-free at 5 years: an unprecedented milestone. 'Phase 3 trials now show improved PFS, OS, and quality of life compared to standard-of-care regimens,' said Paula Rodriguez-Otero, MD, medical coordinator of the Central Unit for Clinical Trials at the University of Navarra, Pamplona, Spain. However, CAR T therapy faces logistical hurdles, including manufacturing delays and the need for specialized infrastructure. High-risk patients with rapid progression or poor bridging therapy responses may still experience suboptimal results, but these challenges are mitigated when CAR T therapy is used earlier in the disease course, before T-cell exhaustion occurs. It's Not One or the Other Both speakers agreed that the future of MM treatment is not about choosing between CAR T and bsAbs but about defining the optimal sequence and integrating both modalities based on patient needs and disease features. BsAbs offer fast, outpatient-ready options for frail or rapidly progressing patients. CAR T therapies, though more complex, offer long remissions and potential treatment-free intervals, especially when used early. Still, Moreau cautioned, many questions remain. What is the best treatment sequence? Should clinicians switch targets — for example from BCMA to GPRC5D — or stick with the same? How should resistance mechanisms, such as antigen loss, be tackled? Can we move toward fixed-duration therapy to reduce costs? Scientific progress must also account for patient priorities. As Solène Clavreul, PhD, noted in an interview with Medscape Medical News , longer survival for myeloma patients means that quality of life is increasingly central. Clavreul is patient advocate and head of medical education and scientific engagement at Myeloma Patients Europe. 'The treatment choices should always be based on research data, but understanding patients' preferences is critical for shared decision-making,' she said. What's Next: BsAb Combinations and Trispecifics 'With 19 new drugs or combinations approved in the past two decades, we've made incredible progress,' said Jesús San Miguel Izquierdo, MD, PhD, director of clinical and translational medicine at the University of Navarra, Pamplona, Spain, in his EHA 2025 Lifetime Achievement Award lecture. Two industry-sponsored studies presented at EHA 2025 point to the next wave of innovation. RedirecTT-1: Dual-Antigen BsAb Combination The phase 2 RedirecTT-1 trial evaluated the combination of talquetamab and teclistamab in patients with extramedullary disease. 'Patients with true extramedullary disease are up to 87% less likely to respond to conventional therapy,' said Shaji Kumar, MD, consultant, professor, and researcher at the Mayo Clinic, Rochester, USA. The combination treatment in the trial yielded an ORR of 78.9% and a complete response rate of 54.4%, with a 12-month PFS rate of 61% and OS rate of 74.5%. Adverse events were not significantly higher than in monotherapy trials, and less frequent dosing (biweekly or monthly) improved tolerability. 'These results showed deep and durable responses in a population with a significant unmet need,' Kumar said. Moreau, who was not involved in the study, added, 'This could be the pivotal trial that leads to approval of the first bsAb combination.' JNJ-5322: First-in-Human Trispecific Antibody JNJ-5322, a trispecific antibody targeting both BCMA and GPRC5D, showed remarkable efficacy in BCMA/GPRC5D-naive patients in a phase 1 trial. 'Despite recent progress, we still need to reduce treatment burden and improve outcomes,' said Rakesh Popat, MD, hematologist at University College Hospital, London, UK. Among patients with triple-class exposed RRMM, the ORR was 100%, with a 70.4% complete response rate and 12-month PFS of 95%. Grade 3/4 infections occurred in 28.6% of patients, but the safety profile — including mild cytokine release syndrome — was manageable. 'JNJ-5322 demonstrated manageable safety and an ORR comparable to CAR T, with convenient, off-the-shelf, weekly dosing, with one step-up dosing to facilitate outpatient dosing,' Popat concluded. Popat, Clavreul, and Kumar reported no relevant financial relationships. Moreaureported honoraria from and advisory board memberships with Janssen, Celgene, Takeda, Amgen, AbbVie, Sanofi, Pfizer, and GSK. Rodriguez Otero reported honoraria from lectures from BMS-Celgene, J&J Innovative Medicines, Sanofi, GSK, Regeneron, and Pfizer; participation in Ad Board meetings for BMS, Janssen, Sanofi, Oncopeptides, Pfizer, Roche, Regeneron, AbbVie, AstraZeneca, H3 Biomedicine, and GSK; consultancy work for BMS-Celgene, AbbVie, Roche, J&J Innovative Medicines, and Pfizer; and research funding and travel support from Pfizer. San Miguel Izquierdo reported participation on advisory boards and consulting services, on behalf of his institution, for AbbVie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, Secura Bio, and Gilead-Kite. The two industry-sponsored studies mentioned were funded by Johnson & Johnson.
